OKYO Pharma
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
14/15 Conduit St Fl 4, London, Greater L...Phone Number
+44 2074952379Website
www.okyopharma.comRevenue
<$5 MillionStock Symbol
OKYOIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About OKYO Pharma
OKYO Pharma is a biopharmaceutical company developing therapeutics to improve the lives of patients with inflammatory eye diseases and ocular pain. They are based in London, United Kingdom.Explore more
OKYO Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OKYO Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once OKYO Pharma has new funding data
Check if OKYO Pharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at OKYO Pharma
OKYO Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when OKYO Pharma launches new products
Earning: See what the market has to say on OKYO Pharma recently announced quarterly report
Click to see if OKYO Pharma had a recent Job posting/layoffs
Check out if OKYO Pharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined OKYO Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to OKYO Pharma
Compare insights from companies similar to OKYO Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OKYO Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OKYO Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OKYO Pharma.
OKYO Pharma financials insights
Gather financial insights about OKYO Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Stock Offering
$2.5M
2025
Other Financing Round
$1.4M
Other Financing Round
$1.9M
OKYO Pharma Tech Stack
A closer look at the technologies used by OKYO Pharma
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Person-Based
Person-Based
OKYO Pharma News & Media
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced CEO presentation at Eyecelerator and leadership participation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, Colorado.OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it will hold a key Scientific Advisory Board (SAB) meeting with leading ophthalmology experts during the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, DC. The SAB meeting,OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company’s ordinary shares on NASDAQ at $1.59, bringing hisOKYO Pharma Announces Director Acquires Shares
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company’s ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OKYO Pharma
Sign Up For FreeTo access detailed company insights
OKYO Pharma is a biopharmaceutical company developing therapeutics to improve the lives of patients with inflammatory eye diseases and ocular pain. They are based in London, United Kingdom.... Read More
